Loading...
•
Feb 28, 2023
AngioDynamics Q3 2023 Earnings Report
AngioDynamics' third quarter results reflected strategic execution amidst market challenges.
Key Takeaways
AngioDynamics reported a 9.1% increase in net sales to $80.7 million, driven by growth in Med Tech and Med Device segments. The company experienced a decrease in gross margin to 50.2% due to inflationary pressures, and a net loss of $9.5 million, or $0.24 per share.
Net sales increased by 9.1% to $80.7 million compared to the prior-year quarter.
Med Tech net sales grew by 16.6%, while Med Device net sales increased by 6.4%.
Gross margin decreased to 50.2%, impacted by inflationary pressures.
GAAP loss per share was $0.24, and adjusted loss per share was $0.03.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Management now expects fiscal year 2023 net sales to be in the range of $338 million to $342 million, gross margin to be approximately 51.0% to 52.0%, and adjusted earnings per share to be in the range of a loss of $0.06 to a loss of $0.01.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...